Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial

Philips, Cyriac Abby; Maiwall, Rakhi; Sharma, Manoj Kumar; Jindal, Ankur; Choudhury, Ashok; Kumar, Guresh; Bhardwaj, Ankit; Mitra, Lalita Gouri; Agarwal, Prashant; Sarin, Shiv Kumar

doi:10.1007/s12072-021-10164-z

Cited by 43 publications

(25 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The subsequent ALBIOS study in critically ill patients with sepsis also concluded that administration of HAS 20% to maintain serum albumin concentration at 30 g/L did not improve 28-and 90-day survival compared with crystalloids alone [5]. The same was true for hospitalised patients with decompensated liver cirrhosis when targeting a serum albumin level > 30 g/L [7].…”

Section: No It Does Notmentioning

confidence: 99%

“…However, the Lactated Ringer Versus Albumin in Early Sepsis Therapy (RASP) study which compared HAS 4% versus crystalloid alone during the first 6 h after ICU admission in 360 cancer patients with severe sepsis or septic shock, confirmed no difference in 7-day or 28-day survival [6]. A recent RCT investigating the effect of HAS 5% versus saline 0.9% in 154 cirrhotic patients with sepsis related hypotension showed improved haemodynamic stabilisation and 7-day survival in the HAS group [7].…”

Section: Myth #4 Albumin Improves Survival In Sepsismentioning

confidence: 99%

See 1 more Smart Citation

Ten myths about albumin

Joannidis

Wiedermann²,

Ostermann

2022

Intensive Care Med

View full text Add to dashboard Cite

Section: No It Does Notmentioning

confidence: 99%

Section: Myth #4 Albumin Improves Survival In Sepsismentioning

confidence: 99%

Ten myths about albumin

Joannidis

Wiedermann²,

Ostermann

2022

Intensive Care Med

View full text Add to dashboard Cite

“…37 Early human serum albumin supplementation has been shown to decrease the incidence of sepsis-related mortality, contributing to better therapeutic achievements in sepsis cases. 38 Recent articles have highlighted the promise of the BAR as a prognostic inflammation-related biomarker in patients with a range of diseases, but its value in the context of sepsis patient evaluation remains unclear. Here, we therefore explored the utility of BAR values as a predictor of sepsis patient prognosis.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Value of the Blood Urea Nitrogen to Albumin Ratio as a Predictor of Mortality in Patients with Sepsis

Han¹,

Cheng²,

Liao³

et al. 2022

JIR

View full text Add to dashboard Cite

At present, simple, accurate, and efficient prognostic tools for the evaluation of cases with early-stage sepsis in the emergency department (ED) are lacking. An increased blood urea nitrogen to albumin ratio (BAR) has previously been shown to be a valuable biomarker with predictive utility in several diseases. The relationship between BAR and sepsis patient outcomes, however, is not well-understood. This exploration was thus developed for the exploration of the link between BAR values and the short-term prognosis of cases with sepsis. Methods: This was a retrospective cohort research of sepsis cases admitted to the West China Hospital of Sichuan University ED from July 2015 to June 2016. Laboratory data were collected upon ED admission, and 7-day all-cause mortality was the primary study endpoint. Relationships between BAR values and APACE II and SOFA scores were generated assessed with correlation coefficient heatmaps. Independent risk factors were identified through multivariate analyses, with the curves of receiver operating characteristic (ROC) being employed to gauge the value of BAR as a predictor of the risk of mortality in sepsis cases. Results: In sum, 801 patients participated in the present investigation. BAR values were strongly correlated with APACHE II and SOFA scores. In a multivariate logistic regression assessment, BAR was identified as an independent predictor of mortality among patients with sepsis (HR=1.032, 95% CI: 1.010-1.055, P=0.004). BAR exhibited an AUC of 0.741 (95% CI: 0.688-0.793, P<0.001) when used to predict patient mortality risk, with 5.27 being the optimal BAR cut-off. Conclusion:We found that BAR can be used as a reliable biomarker to predict mortality in patients with sepsis.

show abstract

“…This negated the Cochrane meta-analysis, but the trial also showed no benefit for the use of albumin overall. A pre-defined sub-group analysis of patients with severe sepsis within the SAFE population showed a survival benefit in the albumin group (91), a finding reflected in a smaller, more recent, single centre study (92) . The SAFE findings Following these results, the Surviving Sepsis Campaign proposed, on a modest evidence allocation, the addition of albumin in patients who continued to require substantial amounts of crystalloid to maintain adequate mean arterial pressure (93).…”

mentioning

confidence: 99%